Literature DB >> 18041018

Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response.

R Bendall1, V Ellis, S Ijaz, P Thurairajah, H R Dalton.   

Abstract

Sequential sera were collected from 18 acute cases of UK-acquired hepatitis E. The virus strains in all cases were of genotype 3. The IgM and IgG response to acute infection were documented over time using EIA kits based on a peptide antigen, pE2, which is derived from a genotype 1 strain of hepatitis E virus (HEV). Ninety-five percentage of acute sera were IgM positive; after 6 months or more only 12% remained positive. The kit was adapted to quantify the IgG response (in WHO U/ml) and to determine antibody avidity. Following acute infection, anti-HEV IgG concentrations rose between 6.9- and 90-fold. IgG avidity was low (<25%) in most acute sera. After 6 months IgG avidity was greater than 50% in all cases. One patient with a poor IgM response and high avidity antibody in acute sera may have had a second HEV infection. Taken together, these results confirm that the pE2-based EIA kits are suitable for diagnosing acute HEV genotype 3 infection. With simple modifications the IgG kit can measure anti-HEV concentration and avidity, which can be used to confirm acute infection. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18041018     DOI: 10.1002/jmv.21033

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  32 in total

1.  Genetic characteristics and pathogenicity of human hepatitis E virus in Nanjing, China.

Authors:  Jia-Bao Geng; Mao-Rong Wang; Ling Wang; Jie Wang; Zhi-Guo Yang; Yan Cheng; Fei Qiao; Min Wang
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 2.  Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections.

Authors:  Christopher M Walker
Journal:  Cold Spring Harb Perspect Med       Date:  2019-09-03       Impact factor: 6.915

3.  Risk factors and immune response to hepatitis E viral infection among acute hepatitis patients in Assiut, Egypt.

Authors:  Salwa S Seif Eldin; Ismail Seddik; Enas A Daef; M T Shata; Marwa Raafat; Laila Abdel Baky; M A Nafeh
Journal:  Egypt J Immunol       Date:  2010

Review 4.  Hepatitis E virus infection.

Authors:  Nassim Kamar; Harry R Dalton; Florence Abravanel; Jacques Izopet
Journal:  Clin Microbiol Rev       Date:  2014-01       Impact factor: 26.132

5.  Origin, antigenicity, and function of a secreted form of ORF2 in hepatitis E virus infection.

Authors:  Xin Yin; Dong Ying; Sébastien Lhomme; Zimin Tang; Christopher M Walker; Ningshao Xia; Zizheng Zheng; Zongdi Feng
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-18       Impact factor: 11.205

Review 6.  Hepatitis E virus in the countries of the Middle East and North Africa region: an awareness of an infectious threat to blood safety.

Authors:  Soha Yazbek; Khalil Kreidieh; Sami Ramia
Journal:  Infection       Date:  2015-06-26       Impact factor: 3.553

Review 7.  Autochthonous hepatitis e virus infections: a new transfusion-associated risk?

Authors:  Jens Dreier; David Juhl
Journal:  Transfus Med Hemother       Date:  2013-12-30       Impact factor: 3.747

8.  A single amino acid substitution changes antigenicity of ORF2-encoded proteins of hepatitis E virus.

Authors:  Jiu-Hong Liang; Xing Dai; Chen Dong; Ji-Hong Meng
Journal:  Int J Mol Sci       Date:  2010-08-12       Impact factor: 5.923

9.  Acute infection by hepatitis E virus with a slight immunoglobulin M antibody response.

Authors:  Yuki Inagaki; Yukio Oshiro; Mamiko Imanishi; Kazunori Ishige; Masaharu Takahashi; Hiroaki Okamoto; Nobuhiro Ohkohchi
Journal:  Clin J Gastroenterol       Date:  2015-07-28

10.  Application of truncated immunodominant polypeptide from hepatitis E virus (HEV) ORF2 in an assay to exclude nonspecific binding in detecting anti-HEV immunoglobulin M.

Authors:  Jin-Shun Pan; Kui Zhang; Jinyong Zhou; Chao Wu; Hui Zhuang; Yi-Hua Zhou
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.